Genetic Characterization of M. tuberculosis Isolates From Participants in a Phase 2b Randomized Trial Evaluating the M72/AS01E Tuberculosis Candidate Vaccine
The Journal of Infectious Diseases · 28.08.2026
DOI: 10.1093/infdis/jiag428 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift The Journal of Infectious Diseases, online erschienen am 28.08.2026. Verfasst von Pierre Wattiau und 17 weiteren Autor:innen. Beteiligte Einrichtung: Vaccine Clinical Laboratory and Assay Portfolio, GSK, Rixensart 1330, Belgium. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: GSK, Aeras, Gates Foundation.
Abstract (Originalsprache)
Background
The efficacy and safety of the M72/AS01E tuberculosis (TB) candidate vaccine were evaluated in the phase 2b randomized, placebo-controlled trial NCT01755598. In the trial, participants with Mycobacterium tuberculosis sensitization by a positive interferon-gamma release assay received either M72/AS01E or placebo (randomized 1:1) and were followed for 3 years. In this descriptive study, we genetically characterized M. tuberculosis isolates from participants who developed pulmonary TB during the trial to assess variability among isolates and evaluate the possibility of preferential progression from infection to active TB by certain strains in M72/AS01E and placebo recipients.
Methods
M. tuberculosis isolates were recovered from sputum samples and underwent DNA extraction and sequencing to assess lineage, antibiotic resistance profile, genetic variation, and genomic clusters.
Results
One hundred isolates (37 M72/AS01E, 63 placebo) were genetically characterized from 50 participants who developed microbiologically confirmed active pulmonary TB during the trial (20 M72/AS01E, 30 placebo). Diverse M. tuberculosis lineages were identified in both M72/AS01E and placebo recipients. No multidrug-resistant strains were detected. Genetic sequences corresponding to the antigenic components of M72/AS01E showed low variation in pepA and high variation in PPE18. However, no apparent preferential distribution of variants was observed in M72/AS01E or placebo recipients. Cluster analyses identified 10 genomic clusters with isolates from >1 participant, illustrating complex transmission dynamics and potential of coinfection by multiple strains within individuals.
Conclusions
This descriptive analysis showed no apparent preferential distribution of local M. tuberculosis strains in M72/AS01E or placebo recipients. These results support the continued development of this candidate vaccine. Clinical Trials Registration The NCT01755598 study was registered at https://Cinicaltrials.gov on 19 December 2012. The trial protocol and statistical analysis plan can be accessed from the trial registration website https://clinicaltrials.gov/study/NCT01755598.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Vaccine Clinical Laboratory and Assay Portfolio, GSK, Rixensart 1330, Belgium.
- Centre for Tuberculosis, National Institute for Communicable Diseases, a division of the National Health Laboratory Service, Johannesburg 2131, South Africa.
- R&D, VxCLAP, GSK, Wavre 1300, Belgium.
- Zambart, Lusaka 10101, Zambia.
- TASK, Cape Town 7500, South Africa.
- Clinical Development, Aeras/IAVI, New York, NY 10004, USA.
ORCID-Profile: Pierre Wattiau, Shaheed V Omar, Lavania Joseph, Marie-Ange Demoitié, Mélanie Gilbert, Helen M Ayles, Andreas H Diacon, Ann M Ginsberg, Mark Hatherill, James C Innes, Mookho Malahleha, Neil Martinson, Monde Muyoyeta, Videlis Nduba, Dereck R Tait, Robert J Wilkinson, François Roman
Förderung
- GSK
- Aeras
- Gates Foundation
- United Kingdom Department for International Development
- Government of the Netherlands
- International Cooperation, and Australian AID
Zitieren
APA
Wattiau, P., Omar, S. V., Joseph, L., Demoitié, M. A., Gilbert, M., Ayles, H. M., Diacon, A. H., Ginsberg, A. M., Hatherill, M., Hellström, E., Innes, J. C., Malahleha, M., Martinson, N., Muyoyeta, M., Nduba, V., Tait, D. R., Wilkinson, R. J., & Roman, F. (2026). Genetic Characterization of M. tuberculosis Isolates From Participants in a Phase 2b Randomized Trial Evaluating the M72/AS01E Tuberculosis Candidate Vaccine. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiag428
Vancouver
Wattiau P, Omar SV, Joseph L, Demoitié MA, Gilbert M, Ayles HM, et al. Genetic Characterization of M. tuberculosis Isolates From Participants in a Phase 2b Randomized Trial Evaluating the M72/AS01E Tuberculosis Candidate Vaccine. The Journal of Infectious Diseases. 2026. doi:10.1093/infdis/jiag428
BibTeX
@article{Wattiau2026,
author = {Wattiau, Pierre and Omar, Shaheed V and Joseph, Lavania and Demoitié, Marie-Ange and Gilbert, Mélanie and Ayles, Helen M and Diacon, Andreas H and Ginsberg, Ann M and Hatherill, Mark and Hellström, Elizabeth and Innes, James C and Malahleha, Mookho and Martinson, Neil and Muyoyeta, Monde and Nduba, Videlis and Tait, Dereck R and Wilkinson, Robert J and Roman, François},
title = {Genetic Characterization of M. tuberculosis Isolates From Participants in a Phase 2b Randomized Trial Evaluating the M72/AS01E Tuberculosis Candidate Vaccine},
journal = {The Journal of Infectious Diseases},
year = {2026},
doi = {10.1093/infdis/jiag428}
}
EUVIMED